Pembrolizumab in Triple-Negative Breast Cancer. Reply

N Engl J Med. 2022 Oct 13;387(15):1436. doi: 10.1056/NEJMc2210919.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans
  • Triple Negative Breast Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab